BetaEval Global: Prospective, Multinational, Observational Cohort Study of Patients Using BETACONNECT.

Purpose: Patients with multiple sclerosis (MS) would benefit from continued long-term treatment with disease-modifying therapies, and autoinjectors may help improve patients' satisfaction with therapy, thereby increasing adherence rates. BETACONNECT is an autoinjector for interferon beta-1b designed to improve the injection experience for patients. The BetaEval Global study assessed medication intake in patients using BETACONNECT to further investigate the value of this autoinjector.

Pregnancy outcomes from the global pharmacovigilance database on interferon beta-1b exposure.

Background: The goal of the present cohort study was to review outcomes of patients exposed to interferon beta-1b during pregnancy.

Methods: Pregnancy cases with exposure to interferon beta-1b reported to Bayer's pharmacovigilance (PV) database from worldwide sources from January 1995 through February 2018 were retrieved for evaluation. Only cases where pregnancy outcomes were unknown at the time of reporting (i.